NCT07482215

Brief Summary

Schistosomiasis remains one of the most important parasitic diseases of public health concern, particularly in developing countries including Egypt. It is caused by a trematode worm (blood flukes) of the genus Schistosoma

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
359

participants targeted

Target at P75+ for all trials

Timeline
17mo left

Started May 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress8%
May 2026Dec 2027

First Submitted

Initial submission to the registry

March 16, 2026

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 19, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

May 1, 2026

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2027

Expected
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

March 19, 2026

Status Verified

March 1, 2026

Enrollment Period

1.3 years

First QC Date

March 16, 2026

Last Update Submit

March 16, 2026

Conditions

Schistosomiasis

Outcome Measures

Primary Outcomes (1)

  • prevalence of human schistosomiasis in the study participants

    using conventional microscopic examination

    24 hours

Study Arms (2)

Schistosoma haematobium

Urine filtration technique (10 ml urine) for diagnosis

Diagnostic Test: Molecular phylogenetic and haplotype analysis

Schistosoma mansoni

Direct wet mount and Kato-Katz thick smear technique (stool) for diagnosis

Diagnostic Test: Molecular phylogenetic and haplotype analysis

Interventions

Molecular phylogenetic and haplotype analysisDIAGNOSTIC_TEST

DNA Sequencing and cox1 Gene Analysis of Schistosoma Isolates

Schistosoma haematobiumSchistosoma mansoni

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All participants presented in Assiut Governorate hospitals

You may qualify if:

  • Patients aged ≥ 5 years of both sexes attending Assiut Governorate hospitals during the study period.
  • Patients clinically suspected of having schistosomiasis (urinary and/or intestinal) or referred for parasitological examination.
  • Individuals (or guardians, in case of minors) who provide written informed consent.
  • Patients willing to provide the required biological samples (urine and/or stool).

You may not qualify if:

  • Patients Received praziquantel within the last 3 months before sample collection
  • Patients with incomplete clinical or epidemiological data.
  • Patients refusing participation or sample collection.
  • Improperly collected, contaminated, or insufficient samples.
  • Patients suffering from severe comorbid conditions that may interfere with the interpretation of results (e.g., advanced hepatic or renal failure).
  • children with congenital urinary or intestinal anomalies.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Schistosomiasis

Interventions

Phylogeny

Condition Hierarchy (Ancestors)

Trematode InfectionsHelminthiasisParasitic DiseasesInfectionsVector Borne Diseases

Intervention Hierarchy (Ancestors)

Biological EvolutionGenetic PhenomenaBiological Phenomena

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principial investigator

Study Record Dates

First Submitted

March 16, 2026

First Posted

March 19, 2026

Study Start

May 1, 2026

Primary Completion (Estimated)

August 1, 2027

Study Completion (Estimated)

December 1, 2027

Last Updated

March 19, 2026

Record last verified: 2026-03